AstraZeneca PLC (LON: AZN, NASDAQ: AZN) reported better-than-expected second-quarter earnings as strong growth in oncology and rare diseases helped offset weaker sales in other parts of the business.
AstraZeneca Slides 9.2% After Wainua Misses Primary Goal in Phase Three Trial
AstraZeneca has seen around £20 billion wiped from its market value following the disappointing late-stage trial results for Wainua, pushing its market capitalisation below £200 billion.
AstraZeneca CEO Cautions Against Imposing Tariffs on Pharmaceuticals
AstraZeneca’s Chief Executive Officer, Pascal Soriot, has cautioned that trade tariffs are ineffective in managing the pharmaceutical sector, as drug manufacturers express concern over potential U.S. duties.
AstraZeneca plans £2bn investment in Beijing despite ongoing China investigation
AstraZeneca has announced plans to invest £2 billion in Beijing, just months after Chinese authorities detained the head of its China division over alleged illegal activities.
AstraZeneca experiences a £2.8 billion reduction in its value due to concerns over expenses.
Shares of AstraZeneca PLC (LSE: AZN) dropped by 1.8%, leading to a £2.8 billion decrease in the company’s market value. This decline was primarily due to ongoing concerns about the
AstraZeneca (LON:AZN) set to acquire a Chinese pharmaceutical company in a multi-billion dollar agreement.
AstraZeneca PLC (LON: AZN) is poised to complete a substantial acquisition, purchasing Gracell Biotechnologies, a Chinese firm renowned for its innovative therapies targeting cancer and autoimmune diseases, in a deal